Business Description
Satellos Bioscience Inc
NAICS : 541713
SIC : 3741
ISIN : CA80401L3083
Compare
Compare
Traded in other countries / regions
MSCL.CanadaMSCLF.USA0IT.Germany IPO Date
2021-08-18Description
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.88 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -57 | |||||
3-Year EPS without NRI Growth Rate | -50 | |||||
3-Year FCF Growth Rate | -48.8 | |||||
Future 3-5Y EPS without NRI Growth Rate | -20.58 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 88.99 | |||||
9-Day RSI | 78.86 | |||||
14-Day RSI | 68.63 | |||||
6-1 Month Momentum % | -28.31 | |||||
12-1 Month Momentum % | 21.78 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.25 | |||||
Quick Ratio | 7.25 | |||||
Cash Ratio | 6.88 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -50.8 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -57.67 | |||||
ROA % | -53 | |||||
ROIC % | -639.8 | |||||
ROC (Joel Greenblatt) % | -126362.64 | |||||
ROCE % | -56.99 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.23 | |||||
Price-to-Tangible-Book | 2.68 | |||||
EV-to-EBIT | -0.62 | |||||
EV-to-EBITDA | -0.62 | |||||
EV-to-FCF | -0.54 | |||||
Price-to-Net-Current-Asset-Value | 2.68 | |||||
Price-to-Net-Cash | 2.87 | |||||
Earnings Yield (Greenblatt) % | -161.29 | |||||
FCF Yield % | -36.38 |